Change of uveitis course after treatment with anti-tumor necrosis factor agents. Data are number (%) unless otherwise indicated.
| Posttreatment Uveitis Course | |||
|---|---|---|---|
| Pretreatment Uveitis Course | Chronic | Recurrent | Remission |
| Adalimumab, n = 43 | |||
| Chronic, n = 26 | 3 (11.5) | 6 (23.1) | 17 (65.4) |
| Recurrent, n = 17 | 0 (0.0) | 5 (29.4) | 12 (70.6) |
| Overall | 3 (7) | 11 (25.6) | 29 (67.4)† |
| Infliximab, n = 42 | |||
| Chronic, n = 30 | 7 (23.3) | 10 (33.3) | 13 (43.3) |
| Recurrent, n = 12 | 0 (0.0) | 7 (58.3) | 5 (41.7) |
| Overall | 7 (16.7) | 17 (40.5) | 18 (42.8)† |
| Overall, n = 85 | |||
| Chronic, n = 56 | 10 (17.8) | 16 (28.6) | 30 (53.6) |
| Recurrent, n = 29 | 0 (0.0) | 12 (41.4) | 17 (58.6) |
| Overall | 10 (11.8) | 28 (32.9) | 47 (55.3) |
↵† p < 0.05.